Send the following on WhatsApp
Continue to Chathttps://forschung.kssg.ch/en/projects/966-incmor0208-301-a-phase-3-randomized-double-blind-placebocontrolled-multicenter-trial-to-evaluate-the-efficacy-and-safety-of-tafasitamab-plus-lenalidomide-in-addition-to-rituximab-versus-lenalidomide-in-addition-to-rituximab-in-patients-with-relapsedrefractory-rr-follicular-lymphoma-fl-grade-1-3a-or-rr-margina/publications